DalCor is pioneering precision medicine for cardiovascular disease. The company is developing dalcetrapib, a unique cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile to maximize clinical benefit.
DalCor is currently conducting the dal-GenE study, a Phase 3 precision medicine cardiovascular o...
DalCor is pioneering precision medicine for cardiovascular disease. The company is developing dalcetrapib, a unique cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile to maximize clinical benefit.
DalCor is currently conducting the dal-GenE study, a Phase 3 precision medicine cardiovascular outcomes trial to determine the efficacy of dalcetrapib in a genetically defined population with cardiovascular disease. The trial has enrolled 6,150 patients post-acute coronary syndrome (ACS).
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.